Our High-alert policy, references the Joint Commission standard MM 01.01.03. Preparing the annual update it was noted that the new standards and mational performance goals do not call out High-alert meds. They do discuss High Risk compounding and Hazardous meds.

Two questions:

Do you see a current standard that calls out the topic of High-alert meds (Maybe we missed something)?

Is it possible that providing polices on specific to HAMS will satify surveyors? We have policies that address many aspects of High-Alert Meds. Example policies would include opioid/anticoag/epidural/oxytocin managemant. Titratable meds and limiting the number of drug concentrations for "HAMS" would be other examples.